# Immunosenescence and metabolic reprogramming in MASLD: an age-dependent immunometabolic vicious cycle and therapeutic opportunities

**Authors:** Yuxin Xu, Qiuxiang Li, Xuehua Jiao

PMC · DOI: 10.3389/fcell.2025.1650677 · Frontiers in Cell and Developmental Biology · 2025-10-08

## TL;DR

This review explores how aging worsens liver disease by linking immune decline and metabolic changes, suggesting new treatment strategies.

## Contribution

The paper introduces an age-dependent immunometabolic cycle as a novel framework for understanding MASLD progression.

## Key findings

- Mitochondrial dysfunction and ROS accumulation drive a self-amplifying immunometabolic cycle in MASLD.
- NLRP3 inflammasome activation in Kupffer cells disrupts adaptive immunity, promoting disease progression.
- Combination therapies targeting multiple nodes in the cycle are needed to treat age-associated MASLD.

## Abstract

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) poses a disproportionately severe burden on the aging population, with a heightened risk of progression to advanced fibrosis and cancer. While immunosenescence and metabolic reprogramming are recognized as key drivers, this review proposes an age-dependent immunometabolic vicious cycle as a critical integrative framework underlying MASLD progression. We hypothesize that at the core of this cycle lies mitochondrial dysfunction and reactive oxygen species (ROS) accumulation, which may initiate a self-amplifying loop: triggering NLRP3 inflammasome activation in Kupffer cells, promoting a context-dependent dysfunction of adaptive immunity. This includes driving CD8+ T cells toward exhaustion in advanced disease and disrupting regulatory T cell (Treg) function, which may range from loss of suppressive capacity to a pro-fibrotic phenotypic switch. Together, these alterations in T cell immunity create a permissive environment for unchecked inflammation and fibrosis. This cycle is further reinforced by gut-liver axis dysfunction. Critically, this framework reveals that overcoming the therapeutic bottleneck in age-associated MASLD necessitates a paradigm shift toward combination therapies that simultaneously target multiple nodes of the cycle.

## Linked entities

- **Proteins:** NLRP3 (NLR family pyrin domain containing 3)
- **Diseases:** Metabolic Dysfunction-Associated Steatotic Liver Disease (MONDO:0013209), cancer (MONDO:0004992)

## Full-text entities

- **Genes:** NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548] {aka AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}
- **Diseases:** mitochondrial dysfunction (MESH:D028361), cancer (MESH:D009369), inflammation (MESH:D007249), fibrosis (MESH:D005355), dysfunction of adaptive immunity (MESH:D018489), MASLD (MESH:D008107), axis (MESH:C566610)
- **Chemicals:** ROS (MESH:D017382)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12540461/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12540461/full.md

## References

33 references — full list in the complete paper: https://tomesphere.com/paper/PMC12540461/full.md

---
Source: https://tomesphere.com/paper/PMC12540461